Global Ophthalmology Drugs Market

Cataract surgery devices include instruments that are used for performing cataract surgery in the treatment of cataracts, a condition in which the lens of the eye becomes progressively opaque, resulting in blurred vision. The main types of cataract surgery devices and equipment are intraocular lens (IOL), ophthalmic viscoelastic device (OVD), phacoemulsification equipment, and femtosecond laser equipment. An ophthalmic viscoelastic device (OVD) is used for performing cataract surgeries. The cataract surgery devices and equipment are used for various surgery types such as extracapsular cataract extraction, phacoemulsification, femtosecond laser, and others. These are used by end-users such as ophthalmology centres, hospitals, and clinics. The cataract surgery devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cataract surgery devices and equipment market statistics, including cataract surgery devices and equipment industry global market size, regional shares, competitors with a cataract surgery devices and equipment market share, detailed cataract surgery devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cataract surgery devices and equipment industry. This cataract surgery devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cataract surgery devices and equipment market size will grow from $6.61 billion in 2022 to $7.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cataract surgery devices and equipment market size is expected to grow to $9.18 billion in 2027 at a CAGR of 6.6%. The major growth driver for this industry has been the global aging population. In 2020, there were 1 billion persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. The cases of cataracts in the geriatric population are also expected to increase in the same proportion. According to World Health Organization, the number of cataract cases is expected to increase by 78% by 2050 in the U.S. alone. This presents a huge market for cataract surgery equipment manufacturers shortly by expanding the customer base due to the fast-growing geriatric population. For instance, the population of China is getting older faster than anywhere else in the world, this presents a huge market for the cataract surgery device manufacturers in China. The major challenge that is faced by this industry is the low level of awareness about eye disorders, especially cataracts. Many people do not have proper knowledge about the symptoms of cataracts and do not get the treatment done. This leads to potential revenue loss for the cataract surgery device manufacturers because of the low number of end-users. For example, as per a study done by NCBI, out of 1552 respondents, 89.9% had heard of cataracts but only 42% were aware of any symptom of cataracts, low awareness of cataract symptoms acts as a major restraint for the cataract surgery equipment industry. The cataract surgery devices and equipment industry has witnessed many positive changes introduced by the market players, the most prominent one being the introduction of laser technology. Laser-assisted cataract surgery is used to gather information about the lens, to make the corneal incision, and for the opening in the lens capsule. The advent of laser technology has caused a significant impact on this industry by bringing in new levels of safety and accuracy and advancing cataract surgery. Femtosecond laser platforms have significantly contributed to the precision of cataract surgeries being performed and may soon surpass the traditional hand-held surgeries. For example, Abbott laboratories which lacked this technology, acquired Optimedica for $250 million to enter the laser cataract surgery devices market after witnessing the huge demand and benefits of laser technology. The ophthalmology and medical equipment industry are subject to numerous stringent regulations and the cataract surgery device equipment manufacturers are no exception. These manufacturers need to comply with several regulations of which the European Medical Device Directives and the U.S. Health Care Compliance is the most prominent one. The European Medical Device Directive requires a manufacturer to meet the harmonized standards for placing their devices in the European market. Similarly the U.S. Health Care Compliance has laid down certain guidelines related to standards of business conduct to be followed by the Pharmaceutical manufacturers. The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates the safety of medical devices in the UK, has issued an urgent notice to Carl Zeiss Meditec, for voluntarily recalling a small batch of its intraocular lenses (IOL). The recall was initiated after the manufacturer detected mislabelling of its IOL, Aaren Scientific EC-3 hydrophobic lens with the wrong dioptric power. Therefore, the manufacturers need to comply strictly with the correct labeling of dioptric power on the IOLs. In October 2020, Katena Products, a US-based manufacturer of ophthalmic surgical instruments, acquired Micro-select instruments for an undisclosed amount. The acquisition would help Katena’s growth in instrument manufacturing vertical. Micro-select instruments is a US-based manufacturer of ophthalmic surgery instruments. Major players in the cataract surgery devices and equipment market are Alcon Inc., Abbott Laboratories, Carl Zeiss Meditech AG, Essilor International S.A., Opcon Corporation, Allergan, Inc., Bausch & Lomb, Inc., NIDEK Co. Ltd., STAAR Surgical Company, and Johnson & Johnson. North America was the largest region in the global cataract surgery devices and equipment market in 2022. Asia-Pacific was the second-largest region in cataract surgery devices and equipment market. The regions covered in the global cataract surgery devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cataract surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The cataract surgery devices and equipment market consist of sales of ophthalmic viscoelastic devices, phacoemulsification equipment, and femtosecond laser equipment that are used for the cataract surgery. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cataract surgery devices and equipment market is segmented - 1) By Type: Intraocular Lens (IOL), Ophthalmic viscoelastic device (OVD), Phacoemulsification Equipment, Femtosecond Laser Equipment 2) By Application: Ophthalmology Centers, Hospitals, Clinics 3) By Surgery Type: Extracapsular Cataract Extraction, Phacoemulsification, Femtosecond Laser, Other Surgery Types

Antiglacoma drug refers to a medication used to treat or prevent glaucoma, a condition in which damage to the optic nerve causes a progressive, irreversible loss of vision. Antiglaucoma drugs are used to treat or prevent glaucoma, a condition in which damage to the optic nerve causes a progressive loss of vision that cannot be reversed. The main types of products in the antiglaucoma drug are alpha agonists, beta-blockers, prostaglandin analogs, combined medication, and others. Alpha-adrenergic agonists are sympathomimetic drugs that activate alpha-adrenergic receptors preferentially. The different types include hospital prescription drugs and over-the-counter drugs and involve different types of disease conditions such as open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, and other types of glaucoma. The antiglaucoma drug market research report is one of a series of new reports from The Business Research Company that provides antiglaucoma drug market statistics, including antiglaucoma drug industry global market size, regional shares, competitors with an antiglaucoma drug market share, detailed antiglaucoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the antiglaucoma drug industry. This antiglaucoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antiglaucoma drugs market size will grow from $14.02 billion in 2022 to $15.04 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antiglaucoma drugs market size is expected to grow to $19.30 billion in 2027 at a CAGR of 6.4%. The incidence of glaucoma increases with age and due to the increase in the geriatric population worldwide, governments are launching initiatives to promote awareness of glaucoma and other eye disorders. For instance, the Vision Health initiative by the Centers for Disease Control and Prevention (CDC) in the USA aimed to prevent eye disorders including glaucoma, and improve overall eye health. In Australia, the government-funded an eye screening program as part of its Vision 2020 initiative to promote awareness and prevent vision loss among the population suffering from glaucoma and other eye disorders. These government initiatives will stimulate awareness among the people about glaucoma driving the market for anti-glaucoma drugs. Anti-glaucoma drugs are facing the risk of patent expiration in the USA and Europe. For instance, travoprost and bimatoprost, which are used in the treatment of glaucoma, will lose their patent in 2021. This will result in the launch of generic forms of drugs that are priced lower than branded drugs thereby reducing the overall market growth. Companies in the antiglaucoma drugs market are developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients. Most of the combination therapies are fixed dose drugs as it offers the patient ease of consumption when compared to non-fixed combinations. Alcon launched a combination drug, Simbrinza which is a fixed combination of Brinzolamide and Brimonidine, to help patients in reducing the intake of multiple drugs for glaucoma. Rockland is a combination of a rho kinase inhibitor and a prostaglandin analog. Combigan is a combination of beta blockers and alpha agonists. Cosopt is a combination of beta-blockers and carbonic anhydrase inhibitors. To get an antiglaucoma drug approved by the United States Food and Drug Administration (USFDA), the drug should have comparable intraocular pressure (IOP) lowering efficacy and benefit-to-hazard ratio concerning the benchmark drug. For instance, Rhopressa (netarsudil) Ophthalmic Solution by Aerie Pharmaceuticals Inc., was approved by the US FDA considering its ability to lower IOP when compared to benchmarked drugs for glaucoma in the market. Major players in the antiglaucoma drugs market are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare, Johnson & Johnson, Merck & Co., Genentech, Inc., Pfizer, Inc., Bayer AG, and Santen Pharmaceuticals Company Ltd. North America was the largest region in the antiglaucoma drugs market in 2022. Middle East is expected to be the fastest-growing region in the global antiglaucoma drugs market during the forecast period. The regions covered in the global antiglaucoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antiglaucoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antiglaucoma drug market consists of sales of dipivefrin, epinephrine, and apraclonidine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antiglaucoma drugs market is segmented - 1) By Product Type: Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Other Types 2) By Disease Condition Type: Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma 3) By Type: Hospital Prescription drugs, Over-the counter drugs

Dry eye medication refers to the drugs or medication that is used to treat dry eye by increasing your eye moisture. A multifactorial condition of the tears and ocular surface known as dry eye causes symptoms such as pain, blurred vision, and tear film instability, as well as the possibility of ocular surface injury. The main types of dry eye medication are aqueous dry eye syndrome and evaporative dry eye syndrome. Dry eye syndrome is a frequent problem that arises when the tears aren't able to keep the eyes lubricated enough. Tears may be insufficient and unstable for a variety of causes. The different types of products include liquid drops, gel, liquid wipes, and eye ointment and are used by hospital pharmacies, eye health clinics, retail pharmacies, and online pharmacies. The dry eye medication market research report is one of a series of new reports from The Business Research Company that provides dry eye medication market statistics, including dry eye medication industry global market size, regional shares, competitors with a dry eye medication market share, detailed dry eye medication market segments, market trends and opportunities, and any further data you may need to thrive in the dry eye medication industry. This dry eye medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global dry eye medication market size will grow from $8.67 billion in 2022 to $9.62 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dry eye medication market size is expected to grow to $13.99 billion in 2027 at a CAGR of 9.8%. The increased number of cases of dry eye disease results in an increased demand for its treatment. Factors such as aging, lack of vitamin A, wearing lenses, eye surgeries, direct contact with dry wind or smoke, and exposing one’s eyes to screens for a long duration increase the occurrence of the dry eye more likely. For example, a survey conducted by the American Academy of Ophthalmology reported that in the USA, nearly 3.2 million women and 1.68 million men, over the age of 50 were affected by dry eye syndrome. Similarly, a study conducted by the Indian Journal of Ophthalmology indicated a 32% prevalence of dry eye disease in the Northern part of India. the rising prevalence of the disease would increase the demand for its treatment and ultimately facilitate the growth of this market. The market for dry eye medication is restricted by the long approval process that is undertaken before any drug is approved by the concerned authority. The standard protocol for testing any new drug demands a series of tests and trials including laboratory tests, animal model tests, and clinical trials. Most drugs fail during clinical trials and only a small percent of them successfully move forward. The cumbersome process of obtaining approvals takes a longer duration of time and restricts the growth of this market. For example, in 2020, Eysuvis, a drug that addresses the short-term treatment needs of patients living with dry eye disease, was approved by the Food and Drug Administration (FDA) after its safety and effectiveness were assessed on more than 2900 patients with the disease in different clinical trials. Similarly, Kissei Pharmaceutical announced to discontinue the development of the KCT-0809 drug after it failed to pass the 3rd phase of clinical trials. Treatment for dry eye disease improved with the incorporation of modern techniques that helped invent advanced hyaluronic acid-based lubricants and lipid emulsions. This technology replaces artificial tears that include isotonic sodium chloride and provides long-lasting lubrication on the surface of the eye. For instance, Allergan, a global pharmaceutical company, launched Refresh Repair Lubricant Eye Drops which are designed to repair and protect the eyes from dry eye disease and improve the clarity of vision and are formulated with carboxymethylcellulose (CMC), hyaluronic acid, and osmoprotectants. These components maintain the health of the ocular surface and safeguard epithelial cells. Advances in technology will have a positive effect on the market. The dry eye medication market is strictly regulated by government agencies such as USFDA (Food and Drug Administration), the European Medicines Agency (EMA), and others. For instance, in the USA, FDA evaluates and approves the drugs meant for dry eye treatment. According to Section 201(g) of the FDA and CFR (Code of federal regulations) act, the licenses are granted to drug manufacturing companies allowing them to sell only those drugs that are safe and clinically effective. FDA demands several tests and several clinical trial rounds before granting such approvals. For example, FDA approved Kala Pharmaceuticals’ eye-related drug called INVELTYS. In July 2022, Alcon, a Switzerland-based ophthalmology company acquired Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals for a deal amount of $60 million. Through this acquisition, Alcon acquires Inveltys treatment of post-operative inflammation and pain following ocular surgery and expands its portfolio. Kala Pharmaceuticals is a US-based pharmacuetical company operating in drug eye medication. Major players in the dry eye medication market are Novartis, Allergan, Otsuka, Santen Pharmaceutical, Auven Therapeutics, Akorn, Valent Pharmaceuticals, Johnson and Johnson Vision, Alcon and Bausch & Lomb. North America was the largest region in the dry eye medication market in 2022. Middle East is expected to be the fastest-growing region in the global dry eye medication market during the forecast period. The regions covered in the global dry eye medication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dry eye medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dry eye medication market consists of sales of polyethylene glycol, polyvinyl alcohol, propylene glycol, carboxymethylcellulose, povidone, glycerine, and mineral oil. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dry eye medication market is segmented - 1) By Type: Aqueous dry eye syndrome, Evaporative dry eye syndrome 2) By end-user: Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies 3) By Product Type: Liquid Drops, Gel, Liquid Wipes, Eye Ointment

An implantable biomaterial is a natural or synthetic material that is used in medical applications to support, enhance, or replace damaged tissue or a biological structure. The main materials in the implantable biomaterials are the materials such as metallic, ceramic, polymers, and natural. Metallic implants in implantable biomaterials refer to the component that is widely selected for orthopedic prosthesis over polymeric biomaterials and traditional ceramic materials and is used for the enhancement of biological activities. The various applications include dental, cardiovascular, ophthalmology, orthopedic, and others. These are used in hospitals, ambulatory surgical centres, and specialty clinics. The implantable biomaterials market research report is one of a series of new reports from The Business Research Company that provides implantable biomaterials market statistics, including implantable biomaterials industry global market size, regional shares, competitors with a implantable biomaterials market share, detailed implantable biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the implantable biomaterials industry. This implantable biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable biomaterials market grew from $113.64 billion in 2022 to $127.97 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable biomaterials market is expected to grow from $198.4 billion in 2027 at a CAGR of 11.6%. The allocation of funds by government organizations in the development of new biomaterials [SR1] contributed to the implantable biomaterials market growth. For instance, Drexel University granted USD 200,000 to the National Science Foundation for research on biomaterial-mediated control over macrophage behavior that affects biomaterial vascularization. The support from government organizations in the development of new biomaterials will drive the implantable biomaterials market. Limitations of biomaterial-based products are a major challenge for the implantable biomaterials market. For instance, metal biomaterials can corrode due to chemical reactions within the body such as enzymes and acids or it can also cause some metal ion toxicity in the body. Polymer biomaterial implants have intensive interaction with the body and can lead to wear and tear and can absorb the important nutrients and water from the blood. Some biomaterial implants can also minimize bone ingrowth or sometimes, implants can loosen over time and become dislodged. These reactions that biomaterials have with the body restrain their use thereby negatively impacting the implantable biomaterials market's growth. Major companies in the implantable biomaterials market are implementing 3D printing of biomaterials in manufacturing. For instance, Evonik is producing 3D printable biomaterials for medical technology that are used for manufacturing medical implants with permanent body contact and temporary body contact line of bioresorbable filaments and powders. Implants with permanent body contact are based on Vestakeep Peek, and with the temporary body, contact is based on Resume. In April 2022, Integer Holdings Corporation, a US-based medical device company, acquired Connemara Biomedical Holdings Teoranta for an undisclosed amount. The acquisition would bring implantable biomaterial technology to Integer’s control and help its growth. Connemara Biomedical Holdings Teoranta is a Ireland-based manufacturer of biomaterials for cardiovascular implants. Major players in the implantable biomaterials market are Evonik Industries AG, Royal DSM, Zimmer Biomet Holdings, Carpenter Technology Corporation, Collagen Matrix, Corbion, BASF SE, Invibio Ltd., and Celanese Corporation. North America was the largest region in the implantable biomaterials market in 2022. Western Europe was the second largest region in the global implantable biomaterials market report. The regions covered in the global implantable biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable biomaterials market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The implantable biomaterial market consists of sales of glass-ceramic and bioactive glasses and calcium phosphate cements. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global implantable biomaterials market is segmented - 1) By Material: Metallic, Ceramic, Polymers, Natural 2) By Application: Dental, Cardiovascular, Ophthalmology, Orthopedic, Other Applications 3) By End-user: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

Implantable drug delivery devices are drug delivery systems implanted under the skin that transmit drugs into the bloodstream from a reservoir. These devices facilitate site specific drug delivery and require smaller doses, thereby minimising side effects. The main products of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilise and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmosis, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The implantable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable drug delivery devices market grew from $18.35 billion in 2022 to $19.58 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable drug delivery devices market is expected to grow from $26 billion in 2027 at a CAGR of 7.3%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was one in three in 2020. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in June 2022, Medtronic plc recalled Cobalt XT, Cobalt, and Crome Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) for the reasons of reports of devices with a short circuit protection (SCP) alert resulting in reduced-energy electric shock delivery, instead of delivering a second phase of high voltage therapy. This may result in failure of device and irregular heartbeat which can lead to more serious issues. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In February 2022, Second Sight Medical Products, a California-based manufacturer of prosthetic devices, merged with Nano Precision Medical. The companies would collaborate to develop drug delivery medical implants.Nano Precision Medical is a US-based developer of NanoPortal drug implant technology. Major players in the implantable drug delivery devices market are Allergan Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck, Genetech Inc., and Psivida. North America was the largest region in the implantable drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global implantable drug delivery devices market report. The regions covered in the global implantable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps, Other Applications 2) By Technology: Diffusion, Osmotic, Magnetic, Other Technologies 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Other Applications

Medical lasers are devices that treat or remove tissues using precisely focused light sources. The main types of medical lasers are solid-state laser systems, gas laser systems, dye laser systems, and diode laser systems. A solid-state laser system is a laser system that uses a gain medium as a solid instead of liquid, as in dye lasers and gas as in gas lasers. The applications involved are surgical, cosmetic, and dental. The end-users involved are ophthalmology, dermatology, gynecology, dentistry, urology, cardiovascular, and others. The medical lasers market research report is one of a series of new reports from The Business Research Company that provides medical lasers market statistics, including medical lasers industry global market size, regional shares, competitors with a medical lasers market share, detailed medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the medical lasers industry. This medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical lasers market grew from $5.56 billion in 2022 to $6.33 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical lasers market is expected to grow from $10.45 billion in 2027 at a CAGR of 13.3%. The increased demand for minimally invasive procedures contributed to the medical lasers market’s growth during the period. The surge in aesthetic and cosmetic procedures propelled the demand for minimally invasive surgeries worldwide. According to the article published by Beautynews in April 2021, the number of facial plastic surgery procedures in the USA in 2020 is approximately 56,084, and the one was the brow lift procedure is nearly 31,404. Thus, the high usage of medical lasers to perform minimally invasive aesthetic and cosmetic surgeries increases the demand for medical lasers. The high cost of surgeries limits the growth of the medical laser market. The high cost of treatments involving medical lasers limited the adoption and demand for lasers used to perform minimally invasive surgeries. For instance, the average cost of LASIK surgery performed in the USA was $1,500 per eye in 2021. Therefore, the high and increasing cost of surgeries is likely to act as a restraint to the growth of the medical lasers market. Major players operating in the market are focusing on developing new innovative products with advanced techniques to serve healthcare professionals and their patients better. For instance, in March 2021, Solta Medical, a division of Bausch Health, launched Clear + Brilliant Touch Laser. The new laser a more comprehensive treatment protocol by providing the benefits of two wavelengths and easing the treatment process. In October 2021, Laser MD Medspa, a US-based medical spa services company, acquired Young Medical Spa for an undisclosed amount. The acquisition would expand the company’s footprint in the state of Pennsylvania by adding four locations. Young Medical is a US-based provider of a full suite of cosmetic and aesthetic treatments, including laser hair removal, botox treatment, and others. Major players in the medical lasers market are El.En. S.p.A, Ellex Medical Lasers Ltd., Lumenis, Alcon Laboratories Inc., AngioDynamics Corp., American Medical Systems Inc., Biolase Inc., Bausch & Lomb Holdings, Cardiogenesis Corporation Inc., and Boston Scientific. North America was the largest region in the medical lasers market in 2022. Asia-Pacific was the second largest region in the global medical lasers market report. The regions covered in the global medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The medical lasers market consists of sales of solid-state laser systems, gas laser systems, dye laser systems, and diode laser systems. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical lasers market is segmented - 1) By Product Type: Solid State Laser Systems, Gas Laser Systems, Dye Laser Systems, Diode Laser Systems 2) By Application: Surgical, Cosmetic, Dental 3) By End Use: Ophthalmology, Dermatology, Gynecology, Dentistry, Urology, Cardiovascular, Other End Users

Minimally invasive surgery devices are surgical tools that require fewer incisions of a smaller size or have a quicker healing process. A minimally invasive medical device is implanted inside the patient during surgery. The main product types of minimally invasive surgery devices are handheld instruments, inflation devices, cutter instruments, guiding devices, electrosurgical devices, auxiliary devices, monitoring and visualization devices. The electrosurgical devices are used to destroy tissue, incise tissue, and control bleeding by coagulating blood. The various applications of minimal invasive surgery devices are laparoscopy, cardiovascular, cosmetic surgery, orthopedic surgery, obstetrics and gynecology, ophthalmology, neurosurgery, urology, and others that are used by end-users such as hospitals, ambulatory surgical centres (ASCS), and research institutes. The minimally invasive surgery devices market research report is one of a series of new reports from The Business Research Company that provides minimally invasive surgery devices market statistics, including minimally invasive surgery devices industry global market size, regional shares, competitors with a minimally invasive surgery devices market share, detailed minimally invasive surgery devices market segments, market trends and opportunities, and any further data you may need to thrive in the minimally invasive surgery devices industry. This minimally invasive surgery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global minimal invasive surgery devices market grew from $28.98 billion in 2022 to $31.64 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The minimal invasive surgery devices market is expected to grow from $39.48 billion in 2027 at a CAGR of 5.7%. The increasing awareness for minimally invasive surgeries among people is driving the minimally invasive surgery devices market. The minimally invasive surgeries require less/tiny cuts in the skin as compared to traditional surgical methods and aid in lesser pain, short hospital stay, less scarring, minimized chances of bleeding and infections, and low tissue damage. According to the German Heart Surgery Report, the heart operations using ECC (extracorporeal circulation) declined due to achievement of established innovations in minimally invasive therapeutic options in heart surgeries. Furthermore, 51.1% of heart valve operations performed out of the total cardiac surgical procedures in Germany were through the single-valve procedure, out of which 38.5% of them were through minimal invasive heart surgeries. Thus, the growing demand for minimally invasive surgery (MIS) will increase the demand for the minimally invasive surgical devices market. The rising trade barriers are expected to have a negative impact on the minimally invasive surgery devices market growth. Many countries placed trade restrictions, especially on imports, to boost local production. For instance, Brexit is likely to lead to more trade restrictions between the UK and other countries in Europe. The US is also implementing several trade restrictions, especially with China, to boost its local production. For instance, the US government imposed an additional 25% tariff on approximately $16 billion worth of imports from China, including minimally invasive surgical devices and equipment and supplies. These trade restrictions are likely to limit the growth of demand going forward by leading to raised prices. Technologically advanced minimally invasive surgery (MIS) devices with improvements in image guidance, fiber-optics, mini dental implants, and robotic control systems are increasingly opted by patients to treat medical conditions such as aneurysms, cardiac procedures, dental and spinal procedures. Less-invasive surgical procedures with enhanced capabilities in the areas of imaging, micromachining, robotic equipment and components, software systems, and others are becoming popular in the healthcare industry. For instance, video-assisted thoracoscopic surgery (VATS), is a minimally invasive surgical procedure performed to completely remove an organ of the human body to treat traumatic injury, infection, or cancer in the lungs. VATS is performed using a video camera where a small tube called a thoracoscope to which the camera is connected, is inserted through a small incision between the ribs. Furthermore, imaging technology involved in MIS, virtual reality (VR) is becoming a significant area of development. Other MIS techniques are applied to perform surgeries such as single-site laparoscopic surgery, robotic surgeries, needlescopic surgery, cardiac and spinal surgeries, and others. Food and Drug Administration Act (FDA) regulates the minimally invasive surgical devices market in the United States of America. The firms manufacturing robotic minimally invasive surgical devices have to list down any possible risks to health and measures taken by them so that the device addresses health hazards if any stated by FDA. However, the FDA is concerned about the health care providers and patients for not being aware of the safety and effectiveness of these devices as they should not be used in mastectomy procedures or prevention or treatment of cancer. Major players in the minimally invasive surgery devices market are Abbott Laboratories, GE Healthcare, Medtronic PLC., Siemens Healthineers, Smith & Nephew PLC., Medtronic PLC., Stryker Corporation, Boston Scientific Corporation, Ethicon Inc., and B. Braun Melsungen AG. North America was the largest region in the minimally invasive surgery devices market in 2022. Western Europe was the second largest region in the global minimally invasive surgery devices market report. The regions covered in the global minimally invasive surgery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the minimally invasive surgery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The minimally invasive surgery devices market consists of sales of graspers, retractors/elevators, dilators, suturing instruments, laparoscopes, gastroscope, cystoscope, and ureteroscop. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global minimal invasive surgery devices market is segmented - 1) By Product Type: Handheld Instruments, Inflation Devices, Cutter Instruments, Guiding Devices, Electrosurgical Devices, Auxiliary Devices, Monitoring & Visualization Devices 2) By Application: Laparoscopy, Cardiovascular, Cosmetic Surgery, Orthopedic Surgery, Obstetrics And Gynecology, Ophthalmology, Neurosurgery, Urology, Other Applications 3) By End Users: Hospitals, Ambulatory Surgical Centers (ASCS), Research Institutes

Pharmaceutical Drugs And Biologics Logistics Market Definition

The pharmaceutical drugs and biologics market consists of sales of pharmaceutical drugs and biologics logistics services by entities (organizations, sole traders and partnerships) that provide pharmaceutical drugs and biologics logistics services. Pharmaceutical drugs and biologics logistics is the logistics of pharmaceutical and biologic drugs from the manufacturer to the end-user. It includes transportation, warehousing, inventory management and other logistics functions.